Milestone Pharmaceuticals Stock Earnings Reports

Milestone Pharma reported its first partial quarter of commercial sales following the December 2025 FDA approval and January 2026 retail availability of CARDAMYST (etripamil) for acute PSVT. Commercial launch activity began mid-February with a ~60-rep national field force. Through April the company has captured ~600 total prescriptions (≈100 in Feb, ≈200 in Mar, ≈300 in Apr) written by over 400 unique prescribers for ~560 unique patients, and estimates ~25% of commercially insured lives have quality coverage following an Express Scripts national formulary win. Early prescriber feedback and patient anecdotes have been positive. Milestone has initiated the Phase III ReVeRa-301 trial in AFib with rapid ventricular rate (self-administered, event-driven design using the approved 70 mg regimen) and expects first patient enrollment in H2 2026. Financially, Milestone ended March 31, 2026 with ~$184M in cash and equivalents (up from $106M at year-end), driven by a $75M payment from a royalty purchase agreement and other financing; Q1 operating cash burn was ~$23.7M. Q1 product revenue was $0.2M; Q1 net loss was ~$26.1M ($0.20/share). Key near-term priorities are expanding payer access and coverage, scaling commercial execution to increase prescription depth and refill rates, advancing the AFib Phase III program, and managing resources to fund operations into H2 2027.